Intervention

Rasagiline

ClinicalTrials.gov intervention label

Clinical trials23

Recruiting0

Common conditions12

Lead sponsors shown15

Clinical trials

23 shown

Efficacy and Safety of Rasagiline in Prodromal Parkinson's DiseaseNCT05611372 · 2023-01-01

Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"NCT03727139 · 2018-11-01

Image Parkinson's Disease Progression StudyNCT02789020 · 2016-12-01

Rasagiline Rescue in Alzheimer's Disease Clinical TrialNCT02359552 · 2015-05-01

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.NCT02278588 · 2014-11-01

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of RasagilineNCT01879748 · 2013-06-01

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseNCT01723228 · 2012-11-01

Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenNCT01652313 · 2012-05-01

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyNCT01497652 · 2012-01-01

Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor FluctuationsNCT01736891 · 2011-11-01

Emotion, Mood and Executive Function in Parkinson's Disease (PD)NCT01385735 · 2011-10-01

Effects of Rasagiline on Sleep Disturbances in Parkinson's DiseaseNCT01442610 · 2011-10-01

Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's DiseaseNCT01178047 · 2011-09-01

The Effect of Rasagiline on Cognition in Parkinson's DiseaseNCT01382342 · 2011-06-01

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)NCT01215227 · 2010-11-18

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOnNCT01055379 · 2010-03-01

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's DiseaseNCT01168596 · 2009-12-01

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseNCT01049984 · 2009-12-01

Effect of Rasagiline on BIA 9-1067 PharmacokineticsNCT01532141 · 2009-11-01

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's PatientsNCT01007630 · 2009-11-01

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseNCT01048229 · 2008-10-01

Rasagiline and Apathy in Parkinson's DiseaseNCT00755027 · 2008-09-01

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)NCT00104273 · 2004-08-01

Common conditions

Parkinson's Disease14 Parkinson Disease4 Alzheimer's Disease2 Dementia1 Depressive Symptoms1 Early-stage Parkinson's Disease1 Idiopathic Parkinson Disease1 Parkinson´s Disease1 Parkinsons's Disease1 REM Sleep Behavior Disorder1 Sleep Disturbances1 Synucleinopathies1

Leading sponsors

Teva Branded Pharmaceutical Products R&D, Inc.3 University of Florida2 Bial - Portela C S.A.1 Brown University1 Chongqing Fortune Pharmaceutical Co., Ltd.1 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1 Georgetown University1 H. Lundbeck A/S1 Lundbeck Italia S.p.A.1 Merck Sharp & Dohme LLC1 Qualissima1 Second Affiliated Hospital, Zhejiang University, School of Medicine1 St. Josef Hospital Bochum1 State University of New York at Buffalo1 Takeda1

Trial status mix

COMPLETED17

TERMINATED3

UNKNOWN2

WITHDRAWN1

Phase mix

PHASE412

PHASE24

PHASE13

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.